MCID: SKN019
MIFTS: 63

Skin Melanoma

Categories: Cancer diseases, Ear diseases, Skin diseases

Aliases & Classifications for Skin Melanoma

MalaCards integrated aliases for Skin Melanoma:

Name: Skin Melanoma 12 51 14
Cutaneous Melanoma 12 28 69
Malignant Melanoma of Ear and/or External Auricular Canal 12
Malignant Melanoma of Skin of Trunk Except Scrotum 12
Malignant Melanoma of Skin of Lower Limb 12
Malignant Melanoma of Skin of Upper Limb 12
Melanoma, Cutaneous Malignant 41
Malignant Lower Limb Melanoma 12
Malignant Upper Limb Melanoma 12
Malignant Scalp Melanoma 12
Malignant Trunk Melanoma 12
Malignant Neck Melanoma 12
Malignant Ear Melanoma 12
Malignant Lip Melanoma 12
Melanoma 69

Classifications:



Summaries for Skin Melanoma

Disease Ontology : 12 A skin cancer that has material basis in melanocytes.

MalaCards based summary : Skin Melanoma, also known as cutaneous melanoma, is related to melanoma, cutaneous malignant 1 and skin/hair/eye pigmentation, variation in, 3, and has symptoms including pruritus and exanthema. An important gene associated with Skin Melanoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Mekinist and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Skin Melanoma

Diseases related to Skin Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 melanoma, cutaneous malignant 1 33.4 BRAF CDKN2A CDKN2B MITF NRAS TP53
2 skin/hair/eye pigmentation, variation in, 3 32.7 MITF TYR
3 acral lentiginous melanoma 32.1 BRAF CDKN2A NRAS
4 melanoma 29.1 BRAF CDKN1A CDKN2A FGF2 MCAM MIA
5 squamous cell carcinoma 27.0 BRAF CDKN1A CDKN2A IGF1R MMP2 MMP9
6 breast cancer 25.6 CASP3 CDKN1A FGF2 IGF1R MDM2 MMP2
7 melanoma, cutaneous malignant 2 12.4
8 melanoma, cutaneous malignant 3 12.4
9 melanoma, cutaneous malignant 5 12.4
10 melanoma, cutaneous malignant 6 12.4
11 melanoma, cutaneous malignant 9 12.4
12 melanoma, cutaneous malignant 8 12.4
13 melanoma, cutaneous malignant 10 12.4
14 melanoma, cutaneous malignant 4 12.2
15 melanoma, cutaneous malignant 7 12.2
16 amelanotic melanoma 10.9
17 brain stem astrocytic neoplasm 10.6 CDKN2A TP53
18 nevus of ota 10.6 BRAF TP53
19 albinism, ocular, with sensorineural deafness 10.6 MITF TYR
20 gallbladder melanoma 10.5 MITF PMEL
21 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
22 halo nevi 10.5 PMEL TYR
23 ring chromosome 7 10.5 MDM2 TP53
24 cerebellar astrocytoma 10.5 BRAF TP53
25 thyroid lymphoma 10.5 CDKN2A CDKN2B TP53
26 scrotal carcinoma 10.5 CDKN2A CDKN2B TP53
27 meningeal melanomatosis 10.5 CDKN2A NRAS TP53
28 spitz nevus 10.5 BRAF CDKN2A TP53
29 leukemia, acute lymphoblastic 3 10.4 CDKN2A CDKN2B TP53
30 hermansky-pudlak syndrome 3 10.4 MITF PMEL TYR
31 anal squamous cell carcinoma 10.4 CDKN2A MDM2 TP53
32 epithelioid cell melanoma 10.4 MCAM MITF TYR
33 dedifferentiated liposarcoma 10.4 CDKN2A MDM2 TP53
34 mucosal melanoma 10.4 BRAF MITF NRAS
35 lentigines 10.4 BRAF MITF TYR
36 vulvar intraepithelial neoplasia 10.4 MMP2 TP53
37 cellular schwannoma 10.4 CDKN2A MDM2 TP53
38 suppressor of tumorigenicity 3 10.4 CDKN1A CDKN2A TP53
39 melanotic neurilemmoma 10.4 PMEL TYR
40 short-rib thoracic dysplasia 4 with or without polydactyly 10.3 CASP3 TP53
41 juvenile pilocytic astrocytoma 10.3 CDKN2A FGF2 TP53
42 giant cell glioblastoma 10.3 BRAF MDM2 TP53
43 liposarcoma 10.3 CDKN2A MDM2 TP53
44 central nervous system melanocytic neoplasm 10.3 CDKN2A NRAS PMEL TYR
45 acute lymphocytic leukemia 10.3 CDKN2A CDKN2B TP53
46 pigmented basal cell carcinoma 10.3 MITF TYR
47 differentiated thyroid carcinoma 10.3 BRAF CDKN2A NRAS TP53
48 endometrial adenocarcinoma 10.3 CDKN2A FGF2 TP53
49 actinic cheilitis 10.3 CDKN1A MDM2 TP53
50 malignant spindle cell melanoma 10.3 MITF NRAS PMEL TYR

Graphical network of the top 20 diseases related to Skin Melanoma:



Diseases related to Skin Melanoma

Symptoms & Phenotypes for Skin Melanoma

UMLS symptoms related to Skin Melanoma:


pruritus, exanthema

GenomeRNAi Phenotypes related to Skin Melanoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CDKN1A CDKN2A PMEL TP53 CASP3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 CASP3 CDKN1A CDKN2A IGF1R PMEL TP53

MGI Mouse Phenotypes related to Skin Melanoma:

43 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 CASP3 BRAF CDKN1A IGF1R MDM2 MCAM
2 behavior/neurological MP:0005386 10.47 CASP3 BRAF MCAM IGF1R MDM2 FGF2
3 cardiovascular system MP:0005385 10.47 CASP3 BRAF CDKN1A IGF1R MDM2 MCAM
4 hematopoietic system MP:0005397 10.47 BRAF CDKN1A CASP3 MDM2 IGF1R MCAM
5 cellular MP:0005384 10.46 CASP3 BRAF FGF2 IGF1R MDM2 MITF
6 endocrine/exocrine gland MP:0005379 10.44 BRAF CDKN1A CASP3 MDM2 IGF1R MITF
7 integument MP:0010771 10.44 CDKN1A CASP3 BRAF MDM2 IGF1R MITF
8 growth/size/body region MP:0005378 10.43 CASP3 BRAF IGF1R MDM2 MMP2 MITF
9 immune system MP:0005387 10.42 CASP3 BRAF MCAM IGF1R MDM2 MITF
10 mortality/aging MP:0010768 10.4 CASP3 BRAF IGF1R MDM2 FGF2 MITF
11 craniofacial MP:0005382 10.31 CASP3 BRAF IGF1R MDM2 MITF MMP2
12 digestive/alimentary MP:0005381 10.3 CASP3 BRAF IGF1R MDM2 MMP9 PTGS2
13 embryo MP:0005380 10.3 BRAF IGF1R MDM2 MITF PTGS2 NRAS
14 neoplasm MP:0002006 10.3 CDKN1A BRAF MDM2 IGF1R MMP9 MMP2
15 nervous system MP:0003631 10.28 CASP3 BRAF IGF1R MDM2 FGF2 MMP2
16 muscle MP:0005369 10.22 CASP3 BRAF IGF1R MDM2 MMP9 MMP2
17 hearing/vestibular/ear MP:0005377 10.18 CASP3 BRAF FGF2 IGF1R MITF CDKN1A
18 no phenotypic analysis MP:0003012 10.18 CDKN1A CASP3 MDM2 MCAM MITF PTGS2
19 liver/biliary system MP:0005370 10.16 BRAF IGF1R MDM2 NME1 PTGS2 NRAS
20 limbs/digits/tail MP:0005371 10.13 IGF1R MDM2 MITF MMP9 NRAS CDKN1A
21 reproductive system MP:0005389 10.07 CASP3 BRAF CDKN1A IGF1R MDM2 MITF
22 pigmentation MP:0001186 10.02 BRAF CASP3 MDM2 MITF NRAS PMEL
23 renal/urinary system MP:0005367 9.97 CASP3 BRAF MDM2 MMP9 PTGS2 CDKN1A
24 skeleton MP:0005390 9.83 BRAF CDKN1A CASP3 MDM2 IGF1R MITF
25 respiratory system MP:0005388 9.81 CASP3 BRAF IGF1R MMP2 MMP9 PTGS2
26 vision/eye MP:0005391 9.44 BRAF CDKN1A CASP3 MITF MMP9 MMP2

Drugs & Therapeutics for Skin Melanoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Mekinist 17 45 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013

Drugs for Skin Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 631)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
2
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
4
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
5
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
6
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
7
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
8
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
9
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
10
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 110942-02-4, 85898-30-2
11
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
12
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
13
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
14
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
15
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
16
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
17
Aminolevulinic acid Approved Phase 4,Phase 2,Not Applicable 106-60-5 137
18
Etanercept Approved, Investigational Phase 4 185243-69-0
19
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
20
Citalopram Approved Phase 4 59729-33-8 2771
21
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 60-00-4, 62-33-9 6049
22
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
23
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
24
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 44462760 44516822
25
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2 571190-30-2 5330286 11431660 5005498
26
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
27
Crizotinib Approved Phase 4,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
28
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
29
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
30
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4 3871
31
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2 231277-92-2, 388082-78-8 208908 9941095
32 triamcinolone acetonide Phase 4,Phase 2,Phase 3,Not Applicable
33 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
34 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Triamcinolone diacetate Phase 4,Phase 2,Phase 3,Not Applicable
41 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable
42 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
43 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
45 Dermatologic Agents Phase 4,Phase 1,Phase 2,Not Applicable
46 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
48 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2380)

# Name Status NCT ID Phase Drugs
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
3 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Completed NCT01515189 Phase 4
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
5 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
6 Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
7 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
8 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Completed NCT02287675 Phase 4 Lymphoseek;Sulfur Colloid
9 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
10 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
11 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
12 Flu Vaccine Responses in the Setting of Melanoma Treatment Recruiting NCT03315975 Phase 4
13 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
14 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
15 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
16 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
17 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4 Triamcinolone Acetonide
18 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
19 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
20 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
21 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
22 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
23 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
24 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
25 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
26 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
27 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
28 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
29 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
30 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit Unknown status NCT01280565 Phase 3 masitinib;Dacarbazine
31 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
32 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
33 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
34 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
35 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
36 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
37 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
38 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
39 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
40 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3
41 Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma Completed NCT00324727 Phase 3 melphalan;regional chemotherapy;systemic chemotherapy
42 PegIntron Versus IntronA in CMAJCC Stage II (EADO 2001/CMII Trial) Completed NCT00221702 Phase 3 PegIntron;intron A
43 Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the Groin Completed NCT00003444 Phase 3
44 Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma Completed NCT01989572 Phase 3
45 Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
46 GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Completed NCT01245062 Phase 3 GSK1120212;Chemotherapy
47 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
48 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
49 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3 Cisplatin;Dacarbazine;Vinblastine
50 Nordic Adjuvant IFN Melanoma Trial Completed NCT01259934 Phase 3 Interferon-alpha2b - 1 year;Interferon-alpha2b - 2 years

Search NIH Clinical Center for Skin Melanoma

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: melanoma, cutaneous malignant

Genetic Tests for Skin Melanoma

Genetic tests related to Skin Melanoma:

# Genetic test Affiliating Genes
1 Cutaneous Melanoma 28

Anatomical Context for Skin Melanoma

MalaCards organs/tissues related to Skin Melanoma:

38
Skin, Lymph Node, Lung, Kidney, Liver, Brain, Testes

Publications for Skin Melanoma

Articles related to Skin Melanoma:

(show top 50) (show all 147)
# Title Authors Year
1
Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013-2016. ( 29120964 )
2018
2
Incidence trends and survival of skin melanoma and squamous cell carcinoma in Cluj County, Romania. ( 28914690 )
2017
3
Cytotoxicity of Labruscol, a New Resveratrol Dimer Produced by Grapevine Cell Suspensions, on Human Skin Melanoma Cancer Cell Line HT-144. ( 29120391 )
2017
4
Natural Compound Licochalcone B Induced Extrinsic and Intrinsic Apoptosis in Human Skin Melanoma (A375) and Squamous Cell Carcinoma (A431) Cells. ( 29027311 )
2017
5
Review and proposal of regional surgical management for melanoma: revisiting of integumentectomy and incontinuity dissection in treatment of skin melanoma. ( 28064397 )
2017
6
Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. ( 28092675 )
2017
7
Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. ( 28511743 )
2017
8
Seasonality of birth for skin melanoma deserves further investigation. ( 28338933 )
2017
9
Metallic copper nanoparticle induces apoptosis in human skin melanoma, A-375 cell line. ( 28067213 )
2017
10
Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. ( 29071268 )
2017
11
Reply to: Seasonality of birth for skin melanoma deserves further investigation. ( 28338928 )
2017
12
Prognostic significance of immunohistochemical epithelial-mesenchymal transition markers in skin melanoma patients. ( 27586584 )
2016
13
A case report of gastroduodenal metastasis from skin melanoma. ( 27264432 )
2016
14
Fasting boosts sensitivity of human skin melanoma to cisplatin-induced cell death. ( 27693581 )
2016
15
Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma. ( 27883322 )
2016
16
Anticancer properties of phospholipase A2 from Daboia siamensis venom on human skin melanoma cells. ( 26884744 )
2016
17
Expression of Molecular Markers of Angiogenesis, Lymphangiogenesis, and Proliferation Depending on the Stage of Skin Melanoma. ( 27590758 )
2016
18
Treatment Outcome and Prognostic Factors for Malignant Skin Melanoma Treated with Radical Surgery. ( 26320440 )
2015
19
Negative HER2/neu amplification using immunohistochemistry and chromogenic in situ hybridization techniques in skin melanoma cases. ( 25684465 )
2015
20
Ginseng marc-derived low-molecular weight oligosaccharide inhibits the growth of skin melanoma cells via activation of RAW264.7 cells. ( 26548345 )
2015
21
Survival of patients with skin melanoma in Europe increases further: Results of the EUROCARE-5 study. ( 26421821 )
2015
22
Bringing Down Cancer Aircraft: Searching for Essential Hypomutated Proteins in Skin Melanoma. ( 26565620 )
2015
23
Calotropis procera extract induces apoptosis and cell cycle arrest at G2/M phase in human skin melanoma (SK-MEL-2) cells. ( 25623835 )
2015
24
Encapsulation of palladium porphyrin photosensitizer in layered metal oxide nanoparticles for photodynamic therapy against skin melanoma. ( 27877834 )
2015
25
ANTIPROLIFERATIVE EFFECT OF INOSITOL HEXAPHOSPHATE ON HUMAN SKIN MELANOMA CELLS IN VITRO. ( 26665395 )
2015
26
Demodex Mite, Rosacea and Skin Melanoma; Coincidence or Association? ( 25917583 )
2015
27
Evaluation of chemopreventive potentials of ethanolic extract of Ruta graveolens against A375 skin melanoma cells in vitro and induced skin cancer in mice in vivo. ( 25609370 )
2015
28
Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. ( 24602025 )
2014
29
Cerium Oxide Nanoparticles Induce Oxidative Stress and Genotoxicity in Human Skin Melanoma Cells. ( 25395198 )
2014
30
Oleanolic acid isolated from ethanolic extract of Phytolacca decandra induces apoptosis in A375 skin melanoma cells: drug-DNA interaction and signaling cascade. ( 24666676 )
2014
31
Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. ( 24922189 )
2014
32
Ambient UVA-induced expression of p53 and apoptosis in human skin melanoma A375 cell line by quinine. ( 23336807 )
2013
33
Ret transgenic mouse model of spontaneous skin melanoma: focus on regulatory T cells. ( 23560814 )
2013
34
Analysis of the application of MMP-9 inhibitor in skin melanoma: experimental study. ( 23658876 )
2013
35
Diagnostic value of intraoperative histopathological examination of the sentinel nodes in breast cancer and skin melanoma-Preliminary results of single centre retrospective study. ( 24416560 )
2013
36
Strategic formulation of apigenin-loaded PLGA nanoparticles for intracellular trafficking, DNA targeting and improved therapeutic effects in skin melanoma in vitro. ( 24070738 )
2013
37
Chemoprevention of skin melanoma: facts and myths. ( 24077511 )
2013
38
Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing. ( 23846221 )
2013
39
Induction of oxidative stress, DNA damage, and apoptosis in a malignant human skin melanoma cell line after exposure to zinc oxide nanoparticles. ( 23493450 )
2013
40
Graveoline Isolated from Ethanolic Extract of Ruta graveolens Triggers Apoptosis and Autophagy in Skin Melanoma Cells: A Novel Apoptosis-Independent Autophagic Signaling Pathway. ( 24343999 )
2013
41
Homeopathic mother tincture of Phytolacca decandra induces apoptosis in skin melanoma cells by activating caspase-mediated signaling via reactive oxygen species elevation. ( 23506692 )
2013
42
Using SEER data to quantify effects of low income neighborhoods on cause specific survival of skin melanoma. ( 23803107 )
2013
43
Ursolic acid differentially modulates apoptosis in skin melanoma and retinal pigment epithelial cells exposed to UV-VIS broadband radiation. ( 24375173 )
2013
44
Optimization of electron paramagnetic resonance imaging for visualization of human skin melanoma in various stages of invasion. ( 22509830 )
2012
45
HOX Gene Aberrant Expression in Skin Melanoma: A Review. ( 23091727 )
2012
46
The role of surgery in the treatment of colorectal metastases from primary skin melanoma. ( 22251405 )
2012
47
Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin. ( 21923754 )
2012
48
Doppler ultrasound flowmetry predicts 15 year outcome in patients with skin melanoma. ( 23904713 )
2012
49
Changes in the levels of N-cadherin and PCNA in skin melanoma cells are mediated through matrix metalloproteinase 9. ( 22866313 )
2012
50
Morphological changes in human skin melanoma treated by high-energy pulsed neodymium laser radiation. ( 21766508 )
2011

Variations for Skin Melanoma

ClinVar genetic disease variations for Skin Melanoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CDKN2A NM_000077.4(CDKN2A): c.301G> T (p.Gly101Trp) single nucleotide variant risk factor rs104894094 GRCh37 Chromosome 9, 21971057: 21971057

Cosmic variations for Skin Melanoma:

9 (show top 50) (show all 1867)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM1176879 TRRAP skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 12
2 COSM5611082 TRRAP skin,trunk,malignant melanoma,NS c.100C>T p.P34S 12
3 COSM328254 TNC skin,trunk,malignant melanoma,NS c.1342C>G p.R448G 12
4 COSM5610746 TBX22 skin,trunk,malignant melanoma,NS c.1352G>T p.G451V 12
5 COSM5610663 SMG7 skin,trunk,malignant melanoma,NS c.2811C>T p.F937F 12
6 COSM5610425 PTPRK skin,trunk,malignant melanoma,NS c.2737G>A p.A913T 12
7 COSM5610317 PTPRD skin,trunk,malignant melanoma,NS c.2595G>A p.M865I 12
8 COSM5142 PTEN skin,trunk,malignant melanoma,NS c.112C>T p.P38S 12
9 COSM231641 PREX2 skin,trunk,malignant melanoma,NS c.1387C>T p.R463C 12
10 COSM5609842 PIK3CG skin,trunk,malignant melanoma,NS c.1419C>T p.F473F 12
11 COSM584 NRAS skin,trunk,malignant melanoma,NS c.182A>G p.Q61R 12
12 COSM585 NRAS skin,trunk,malignant melanoma,NS c.183A>T p.Q61H 12
13 COSM571 NRAS skin,trunk,malignant melanoma,NS c.37G>A p.G13S 12
14 COSM5049808 NF1 skin,ear,malignant melanoma,NS c.3652C>T p.Q1218* 12
15 COSM6503455 NF1 skin,trunk,malignant melanoma,NS c.2131C>T p.R711C 12
16 COSM5049807 NF1 skin,ear,malignant melanoma,NS c.3097C>T p.Q1033* 12
17 COSM5609545 NF1 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 12
18 COSM5609467 MTOR skin,trunk,malignant melanoma,NS c.2638A>G p.T880A 12
19 COSM5609451 MSH6 skin,trunk,malignant melanoma,NS c.4004A>G p.E1335G 12
20 COSM232755 MAP2K1 skin,trunk,malignant melanoma,NS c.607G>A p.E203K 12
21 COSM5609259 KRAS skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12
22 COSM5609255 KIT skin,trunk,malignant melanoma,NS c.575G>A p.G192D 12
23 COSM5609145 IL36A skin,trunk,malignant melanoma,NS c.359C>T p.S120F 12
24 COSM109660 GRIN2A skin,ear,malignant melanoma,NS c.4097C>T p.P1366L 12
25 COSM106626 GRIN2A skin,ear,malignant melanoma,NS c.1959G>A p.M653I 12
26 COSM110485 GRIN2A skin,ear,malignant melanoma,NS c.3217G>A p.E1073K 12
27 COSM5609011 GRIN2A skin,trunk,malignant melanoma,NS c.2252G>A p.G751E 12
28 COSM5608954 GNAQ skin,trunk,malignant melanoma,NS c.264G>T p.Q88H 12
29 COSM1205523 EPHB4 skin,trunk,malignant melanoma,NS c.2177C>T p.S726L 12
30 COSM5608400 EPHA3 skin,trunk,malignant melanoma,NS c.2525G>A p.R842Q 12
31 COSM141892 CNR1 skin,ear,malignant melanoma,NS c.145C>T p.P49S 12
32 COSM141856 CHRM3 skin,ear,malignant melanoma,NS c.1741T>A p.F581I 12
33 COSM13830 CDKN2A skin,trunk,malignant melanoma,NS c.341C>A p.P114H 12
34 COSM13281 CDKN2A skin,trunk,malignant melanoma,NS c.205G>T p.E69* 12
35 COSM12503 CDKN2A skin,trunk,malignant melanoma,NS c.334C>G p.R112G 12
36 COSM478 BRAF skin,ear,malignant melanoma,NS c.1801A>G p.K601E 12
37 COSM476 BRAF skin,trunk,malignant melanoma,NS c.1799T>A p.V600E 12
38 COSM471 BRAF skin,ear,malignant melanoma,NS c.1790T>G p.L597R 12
39 COSM27639 BRAF skin,ear,malignant melanoma,NS c.1780G>A p.D594N 12
40 COSM1448615 BRAF skin,trunk,malignant melanoma,NS c.1390G>A p.G464R 12
41 COSM1125 BRAF skin,ear,malignant melanoma,NS c.1790T>A p.L597Q 12
42 COSM3522693 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 12
43 COSM5611083 skin,trunk,malignant melanoma,NS c.100C>T p.P34S 12
44 COSM99924 skin,trunk,malignant melanoma,NS c.856G>A p.E286K 12
45 COSM5609544 skin,trunk,malignant melanoma,NS c.7189+1G>A p.? 12
46 COSM5609258 skin,trunk,malignant melanoma,NS c.130G>A p.V44I 12
47 COSM5609546 skin,trunk,malignant melanoma,NS c.568+1G>A p.? 12
48 COSM5608955 skin,trunk,malignant melanoma,NS c.177G>T p.Q59H 12
49 COSM1176880 skin,trunk,malignant melanoma,NS c.3251C>T p.S1084L 12
50 COSM5610662 skin,trunk,malignant melanoma,NS c.2823C>T p.F941F 12

Expression for Skin Melanoma

Search GEO for disease gene expression data for Skin Melanoma.

Pathways for Skin Melanoma

Pathways related to Skin Melanoma according to GeneCards Suite gene sharing:

(show top 50) (show all 88)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 BRAF CASP3 CDKN2A FGF2 IGF1R MDM2
2
Show member pathways
13.87 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
3
Show member pathways
13.77 BRAF CDKN1A CDKN2A CDKN2B FGF2 IGF1R
4
Show member pathways
13.41 BRAF CASP3 CDKN1A FGF2 MMP2 MMP9
5
Show member pathways
13.12 BRAF FGF2 IGF1R MDM2 NRAS TP53
6
Show member pathways
13.04 CASP3 CDKN1A FGF2 IGF1R MDM2 NRAS
7
Show member pathways
12.92 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
8
Show member pathways
12.88 CASP3 CDKN1A CDKN2A IGF1R MDM2 NRAS
9 12.82 BRAF CASP3 FGF2 IGF1R NRAS TP53
10
Show member pathways
12.8 BRAF CDKN1A CDKN2A CDKN2B FGF2 IGF1R
11
Show member pathways
12.79 CDKN1A FGF2 MDM2 NRAS TP53
12
Show member pathways
12.77 BRAF CASP3 NRAS PTGS2 TP53
13
Show member pathways
12.65 CDKN1A FGF2 MMP2 NRAS TP53
14
Show member pathways
12.65 CASP3 CDKN1A FGF2 MMP9 NRAS PTGS2
15
Show member pathways
12.63 CDKN1A CDKN2A CDKN2B MDM2 TP53
16
Show member pathways
12.57 BRAF CASP3 MDM2 NRAS TP53
17
Show member pathways
12.54 BRAF CDKN1A MDM2 NRAS TP53
18
Show member pathways
12.51 CASP3 IGF1R MDM2 NRAS TP53
19 12.51 CASP3 CDKN1A CDKN2A MDM2 MMP9 NRAS
20
Show member pathways
12.5 BRAF CDKN1A CDKN2A IGF1R MDM2 MMP2
21 12.49 CDKN1A CDKN2A CDKN2B NRAS TP53
22
Show member pathways
12.44 CDKN1A IGF1R MDM2 TP53
23
Show member pathways
12.44 CASP3 CDKN1A CDKN2A MDM2 TP53
24
Show member pathways
12.43 CDKN1A MITF NRAS TP53 TYR
25 12.43 CDKN1A CDKN2A CDKN2B MDM2 TP53
26
Show member pathways
12.41 CDKN1A CDKN2A CDKN2B TP53
27 12.35 CDKN1A IGF1R MDM2 MITF MMP9 TP53
28
Show member pathways
12.33 BRAF CASP3 MITF NRAS TP53
29
Show member pathways
12.31 CASP3 CDKN1A MDM2 TP53
30 12.3 CASP3 CDKN1A CDKN2A CDKN2B MDM2 NRAS
31
Show member pathways
12.29 BRAF CASP3 CDKN1A IGF1R MDM2 NRAS
32 12.25 CDKN1A CDKN2A CDKN2B MDM2 NRAS TP53
33
Show member pathways
12.23 BRAF IGF1R NRAS TP53
34 12.21 BRAF CASP3 MDM2 TP53
35
Show member pathways
12.21 BRAF CDKN1A CDKN2A MDM2 NRAS TP53
36
Show member pathways
12.2 BRAF CASP3 NRAS TP53
37 12.19 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2
38
Show member pathways
12.18 CDKN1A IGF1R MDM2 MMP2
39 12.17 BRAF CASP3 CDKN1A MMP2 MMP9 PTGS2
40 12.14 CDKN1A CDKN2A MDM2 MMP2 TP53
41
Show member pathways
12.14 BRAF CDKN1A CDKN2B IGF1R MDM2 NRAS
42 12.13 CDKN1A MDM2 MMP2 TP53
43 12.13 CDKN1A CDKN2A MDM2 TP53
44 12.12 BRAF CDKN1A NRAS TP53
45 12.09 CDKN1A CDKN2A MDM2 NRAS TP53
46 12.08 CASP3 MMP9 PTGS2 TP53
47 12.05 BRAF CASP3 NRAS PTGS2
48 12.04 CDKN1A FGF2 MMP2 MMP9 PTGS2 TP53
49 11.98 BRAF CDKN1A CDKN2A IGF1R MDM2 TP53
50 11.97 CASP3 CDKN1A CDKN2B PTGS2 TP53

GO Terms for Skin Melanoma

Cellular components related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.47 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2

Biological processes related to Skin Melanoma according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.98 CASP3 CDKN2A MMP9 PTGS2 TP53
2 angiogenesis GO:0001525 9.94 FGF2 MCAM MMP2 PTGS2
3 negative regulation of cell proliferation GO:0008285 9.88 CDKN1A CDKN2A CDKN2B NME1 PTGS2 TP53
4 cell cycle arrest GO:0007050 9.87 CDKN1A CDKN2A CDKN2B TP53
5 response to organic cyclic compound GO:0014070 9.84 CASP3 CDKN1A PTGS2 TP53
6 wound healing GO:0042060 9.83 CASP3 FGF2 TP53
7 response to organic substance GO:0010033 9.83 CASP3 CDKN1A PTGS2
8 protein sumoylation GO:0016925 9.82 CDKN2A MDM2 MITF
9 cellular response to drug GO:0035690 9.8 BRAF NME1 TP53
10 response to glucocorticoid GO:0051384 9.8 CASP3 CDKN1A PTGS2
11 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.79 CDKN1A MDM2 TP53
12 response to cAMP GO:0051591 9.77 BRAF NME1 TYR
13 cellular response to heat GO:0034605 9.75 CDKN1A PTGS2 TP53
14 embryo implantation GO:0007566 9.73 MMP2 MMP9 PTGS2
15 response to drug GO:0042493 9.73 CASP3 CDKN1A MDM2 NME1 PTGS2 TP53
16 response to organonitrogen compound GO:0010243 9.72 CDKN1A PTGS2 TP53
17 response to antibiotic GO:0046677 9.69 CASP3 MDM2 TP53
18 cellular response to gamma radiation GO:0071480 9.67 CDKN1A MDM2 TP53
19 melanin biosynthetic process GO:0042438 9.65 PMEL TYR
20 negative regulation of fibroblast migration GO:0010764 9.65 BRAF FGF2
21 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.65 CASP3 CDKN1A CDKN2A
22 amyloid fibril formation GO:1990000 9.63 CDKN2A MDM2
23 response to X-ray GO:0010165 9.63 CASP3 CDKN1A TP53
24 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.61 MDM2 MMP2 MMP9
25 signal transduction by p53 class mediator GO:0072331 9.59 CDKN1A TP53
26 negative regulation of phosphorylation GO:0042326 9.54 CDKN1A CDKN2A CDKN2B
27 cellular response to actinomycin D GO:0072717 9.52 MDM2 TP53
28 replicative senescence GO:0090399 9.5 CDKN1A CDKN2A TP53
29 response to UV GO:0009411 9.46 CASP3 CDKN1A TP53 TYR
30 Ras protein signal transduction GO:0007265 9.35 CDKN1A CDKN2A FGF2 NRAS TP53
31 negative regulation of apoptotic process GO:0043066 9.28 BRAF CASP3 CDKN1A IGF1R MDM2 MITF
32 phosphorylation GO:0016310 10.09 BRAF CDKN1A CDKN2A CDKN2B IGF1R NME1
33 positive regulation of gene expression GO:0010628 10 BRAF CDKN2A MDM2 MITF TP53

Molecular functions related to Skin Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.8 BRAF CDKN1A CDKN2A CDKN2B IGF1R NME1
2 identical protein binding GO:0042802 9.8 BRAF IGF1R MDM2 MMP9 NME1 PMEL
3 protein kinase binding GO:0019901 9.77 CDKN1A CDKN2A CDKN2B NME1 TP53
4 disordered domain specific binding GO:0097718 9.13 CDKN2A MDM2 TP53
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.92 CASP3 CDKN1A CDKN2A CDKN2B
6 protein binding GO:0005515 10.09 BRAF CASP3 CDKN1A CDKN2A CDKN2B FGF2

Sources for Skin Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....